Wyeth's Prevenar-13 proves effective in Phase III studies
This article was originally published in Scrip
Wyeth's new pneumococcal vaccine, Prevenar-13, is able to elicit a robust immune response to all 13 serotypes it contains, according to Phase III data presented recently at the annual meeting of the European society for paediatric infectious diseases (ESPID).
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.